Scarica l'app Stockscreener
477.92
4.17%
19.11
Dopo l'orario di chiusura:
475.01
-2.91
-0.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$458.81
Aprire:
$459.69
Volume 24 ore:
1.62M
Relative Volume:
1.15
Capitalizzazione di mercato:
$121.26B
Reddito:
$11.74B
Utile/perdita netta:
$3.68B
Rapporto P/E:
33.68
EPS:
14.1888
Flusso di cassa netto:
$3.34B
1 W Prestazione:
+1.71%
1M Prestazione:
+2.04%
6M Prestazione:
+23.93%
1 anno Prestazione:
-0.67%
Intervallo 1D:
$459.00
$478.28
Intervallo di 1 settimana:
$457.74
$478.72
Portata 52W:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
2 Top Healthcare Stocks to Buy in February - The Globe and Mail
Biotech Stocks To Add to Your WatchlistFebruary 6th - MarketBeat
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Autoimmune Pipeline Expansion With WuXi Biologics - simplywall.st
Five things for pharma marketers to know for Friday, February 6, 2026 - Medical Marketing and Media
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Finviz
Does WuXi Trispecific T-cell Engager Deal Reshape the Bull Case for Vertex Pharmaceuticals (VRTX)? - simplywall.st
Vertex’s CRISPR treatment for sickle cell disease hits unexpected roadblock - statnews.com
Is Vertex Pharmaceuticals (VRTX) Pricing Reflect Long Term Cash Flow Potential After Recent Pullback - Yahoo Finance
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug - MSN
The Truth About Vertex Pharma: Why Wall Street Suddenly Can’t Shut Up - AD HOC NEWS
Callan Family Office LLC Has $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Machina Capital S.A.S. Acquires Shares of 11,167 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Brookdale Senior Living (BKD) - The Globe and Mail
Rep. David Taylor Sells Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock - MarketBeat
WUXI BIO, Vertex Pharmaceuticals Sign License & Research Service Agreement for T-cell Engager - AASTOCKS.com
Biopharma bites: Updated data for Ultragenyx's gene therapy, AI newco's $13.5M seed round, plus more from NMD, Vertex - FirstWord Pharma
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? - Yahoo Finance
Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today - Yahoo Finance
WuXi licenses trispecific immune engager to Vertex - The Pharma Letter
Vertex (VRTX) Secures Exclusive Rights for Innovative Autoimmune Treatment - GuruFocus
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by WCM Investment Management LLC - MarketBeat
Mediolanum International Funds Ltd Purchases 3,050 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
WuXi Biologics Jumps On Pact With Vertex Pharma For T-Cell Engager In Autoimmune Disease - Nasdaq
Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica - GlobeNewswire Inc.
WuXi Biologics and Vertex Pharmaceuticals Partner to Develop T-Cell Engager Immunotherapies - geneonline.com
WuXi Biologics Inc. and Vertex Pharmaceuticals Incorporated Sign License and Research Service Agreement for T-Cell Engager - marketscreener.com
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Healthcare Giant with 9.45% Potential Upside - DirectorsTalk Interviews
Top Biotech Stocks To Watch TodayFebruary 2nd - MarketBeat
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Growth and Breakout Opportunity - Chartmill
Principal Financial Group Inc. Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Why analysts are positive on Vertex Pharmaceuticals Incorporated (VRTX)’s story - MSN
Atle Fund Management AB Reduces Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Holdings Lifted by National Pension Service - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by TD Waterhouse Canada Inc. - MarketBeat
Vertex Pain Setback Prompts Fund Exit And Recheck Of Valuation Gap - Yahoo Finance
Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)'s Story - Finviz
Biotech Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)’s Story - Insider Monkey
Welch & Forbes LLC Buys 3,102 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
AustralianSuper Pty Ltd Trims Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today - Yahoo Finance
10 Most Profitable Healthcare Stocks to Buy - Insider Monkey
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Fidelis Capital Partners LLC - MarketBeat
Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals - The Globe and Mail
Best Biotech Stocks To Watch NowJanuary 29th - MarketBeat
What's Driving the Market Sentiment Around Vertex Pharmaceuticals Inc? - Benzinga
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Fund Exit And Setback For Journavx Pain Label - simplywall.st
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Strategic Advisors LLC - MarketBeat
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Value Case - Chartmill
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.46%
1.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):